Background: Frailty is increasing in prevalence and because frail patients are often
perceived to have a less favorable benefit/risk profile, they may be less likely to
receive new pharmacological treatments. We investigated the efficacy and tolerability
of dapagliflozin according to frailty status in patients with heart failure and mildly
reduced and preserved ejection fraction randomized in DELIVER.
